Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Reports Q4 revenue $12.8M, consensus $14.4M. “We are proud to have helped thousands of women with postpartum depression in 2024. ZURZUVAE is ...

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.